or Try an Advanced Search...

    Gabaa Receptor Positive Allosteric Modulators Stocks List

    Symbol Grade Name % Change
    AQST A Aquestive Therapeutics, Inc. -2.28
    ELYM B Eliem Therapeutics, Inc -3.10
    ESPR D Esperion Therapeutics, Inc. 9.42
    SAGE F Sage Therapeutics, Inc. 0.47
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Drugs Epilepsy Seizure Adjunctive Therapy Amyotrophic Lateral Sclerosis Anaphylaxis Anticonvulsants Antidepressants Atherosclerosis Biotechnology Cardiology Central Nervous System Disorders Chloroarenes Cholesterol Chronic Pain Clinical Development Diabetes Disease Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Gabaa Receptor Positive Allosteric Modulators stocks.

    Symbol Grade Name Weight
    JFWD D Jacob Funds Inc. Jacob Forward ETF 3.63
    PSIL F AdvisorShares Psychedelics ETF 3.17
    LABD B Direxion Daily S&P Biotech Bear 3X Shares 2.59
    BBP F BioShares Biotechnology Products Fund 1.53
    XBI D SPDR S&P Biotech ETF 0.75
    View all Gabaa Receptor Positive Allosteric Modulators ETFs...
    Compare ETFs
    Compare BBP to XBI Compare JFWD to XBI Compare PSIL to LABD

        Gabaa Receptor Positive Allosteric Modulators Stocks Recent News

        Date Stock Title
        Apr 23 ESPR Esperion to Report First Quarter 2024 Financial Results on May 7
        Apr 21 ESPR 11 Best Low Price Pharma Stocks To Invest In
        Apr 18 SAGE Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
        Apr 18 SAGE Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
        Apr 18 SAGE Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)
        Apr 17 SAGE Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
        Apr 17 SAGE BofA downgrades Sage to underperform, cites failed Parkinson's study
        Apr 17 SAGE Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
        Apr 17 AQST Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
        Apr 17 SAGE Sage’s cognition drug fails in Parkinson’s study
        Apr 17 SAGE Sage drops after mid-stage setback for Parkinson’s disease candidate
        Apr 17 SAGE Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Drugs Epilepsy Seizure Adjunctive Therapy Amyotrophic Lateral Sclerosis Anaphylaxis Anticonvulsants Antidepressants Atherosclerosis Biotechnology Cardiology Central Nervous System Disorders Chloroarenes Cholesterol Chronic Pain Clinical Development Diabetes Disease Disorders
        Gabaa Receptor Positive Allosteric Modulators

        GABAA Receptor Positive Allosteric Modulators (PAMs) are a class of drugs that act on the GABA-A receptor to enhance its activity. These drugs are used to treat a variety of conditions, including anxiety, insomnia, epilepsy, and alcohol withdrawal. They work by increasing the activity of the GABA-A receptor, which helps to reduce the excitability of neurons in the brain and promote relaxation.

        Browse All Tags